Overview
Dendrogenix is a Belgian biopharmaceutical company founded in 2018 specializing in the development of Dendrogenins, cholesterol derivatives that stimulate cell differentiation in the immune and nervous systems. The company focuses on preclinical and clinical development of these molecules, primarily targeting auditory degeneration and neurological dysfunction with unmet medical needs. Dendrogenix has developed international research partnerships with academic centers including GIGA-Neurosciences at the University of Liège and the University of Tübingen in Germany.
Key people
In the news
- Just few weeks to go until BIO-Europe 2026 ! Dendrogenix team will be in Cologne for BIO-Europe 2026. As DX243 progresses through Phase 2a clinical development, we are actively seeking opportunities to engage with: ✅ Biopharma partners ✅ Investors and strategic financers ✅ Licensing and co-development partners We would be pleased to discuss: 🔬 DX243 and its clinical development program in age-related hearing loss 🧠 Dendrogenins and their therapeutic potential in neurological disorders 🤝 Strategic partnering opportunities 📍
- Dendrogenix will be attending BIO-Europe 2026 in Cologne. We are pleased to announce that Dendrogenix will participate in BIO-Europe 2026, taking place in Cologne, Germany. Over the coming weeks, we look forward to engaging with biotechnology, pharmaceutical and investment partners as we continue advancing DX243, our lead candidate for age-related hearing loss, currently in Phase IIa clinical development. BIO-Europe remains one of the key partnering events for the life sciences industry, creating opportunities to exchange
- DX243 demonstrates beneficial effects in preclinical models of ischemic stroke. 📢 Dendrogenix reports the publication of new preclinical results highlighting the activity of DX243, a first-in-class compound, in both in vitro and in vivo stroke models. Published in Frontiers in Stroke (June 2026), this study is a preclinical proof of concept of DX243 in ischemic stroke. 🔬The study reports : ✅ improved neuronal survival and bioenergetics ✅ significant reduction in infarct volume ✅ preservation of motor coordination ✅ effects on
Something wrong or missing? Send an update. Fixed within 24 hours.